🎉 We've launched!
Welcome to a whole new world of streamlined practice management
🎉 We've launched!
Welcome to a whole new world of streamlined practice management
🎉 We've launched!
Welcome to a whole new world of streamlined practice management
Measures Guide
Generalised Anxiety Disorder Assessment (GAD-7)
Understanding Anxiety: Exploring Symptoms Through the GAD-7 Self-Report Measure
Understanding Anxiety: Exploring Symptoms Through the GAD-7 Self-Report Measure
Understanding Anxiety: Exploring Symptoms Through the GAD-7 Self-Report Measure
By Maggie Bowman
Psychology Research Assistant
Published
Published
14 Jan 2023
14 Jan 2023
TL;DR: Summary
✅ Available on Bravely Connect
The GAD-7 is a self-report measure used to assess symptoms of generalised anxiety disorder. It consists of 7 questions that ask the client to report how often over the last two weeks they have been bothered by certain symptoms. The measure is scored out of a maximum of 21, with scores of 8 and above being recognized as the optimal cut-off for clinically relevant levels of anxiety. Research suggests that the GAD-7 is able to screen for generalised anxiety disorder and other anxiety disorders to a relatively good level of accuracy, however it’s not considered accurate for low-level anxiety. It has good reliability and criterion, construct, factorial, and procedural validity. The GAD-7 was developed based on the Patient Health Questionnaire (PHQ-9) and there are over 50 translations of the measure available.
Highlights
📏 Lengths: 7 questions (2-5 minutes)
📋 Administration: Self-Report
🎯 Uses: For monitoring symptoms of generalized anxiety, but can also be used for panic, social anxiety, and PTSD.
⚠️ Important Caveats: Not accurate for low-level anxiety
✅ Available in Bravely Connect? Yes
🌏 Culturally Applicable? No (Western-Centric)
💬 Translations? 50+
The GAD-7 Question type and length
The client is presented with 7 questions, and for each question the client is asked to report how often over the last two weeks they have been bothered by the problem.
All questions are statements with the same 4 subjective answers:
Not at all
Several Days
More than half the days
Nearly every day
For the full list of questions check out the measures on Bravely Connect, or follow the following link to the original unautomated version: GAD-7
What does the GAD-7 measure
The GAD-7 measures severity of anxiety symptoms. Research suggests that it’s able to screen for generalised anxiety disorder, but also a variety of other anxiety disorders to a relatively good level of accuracy.
GAD-7 Factor structure
In academic research, factor analyses have been conducted to identify what the underlying constructs are that the GAD-7 is measuring. Across two studies, traditional factor analyses have found a one-factor structure with all questions mapping onto anxiety. However, one of these studies found, via an exploratory graph analysis, a two-factor structure of cognitive-emotional and somatic anxiety. The most relevant symptoms within these factor structures were ‘worrying too much’ and ‘difficulty relaxing’.
The history and theory behind GAD-7
The GAD-7 was developed by Spritzer et al. as a brief measure for assessing generalised anxiety disorder. It was modelled based on the Patient Health Questionnaire (PHQ-9), which measures depression, and was developed because there was no brief clinical measure for assessing generalised anxiety disorder at the time.
They validated their measure in 15 primary care clinics in the United States based on a sample of 2740 adult patients. Criterion and construct validity were established by comparing the diagnoses made via their GAD self-report scale (GAD-7) with those made by independent mental health professionals, functional status measures, disability days, and health care use.
They found the measure to have good reliability, and criterion, construct, factorial, and procedural validity. In factor analyses, they found that generalised anxiety disorder and depression symptoms often co-occurred, but they were found to be distinct dimensions. They also found that the self-report nature of the questionnaire was in strong agreement with interview-administered versions of the scale.
Research has since suggested that the first 4 questions in the GAD-7 align well with anxious disorders, but this is less the case for the final 3 questions. On the back of this, an even shorter version of the GAD-7 was developed called the GAD-2, consisting of just 2 questions.
There are currently over 50 translations of the GAD-7 (find them here)
GAD-7 Scoring Interpretation
The following scores are given for each answer on the GAD-7:
Not at all = 0
Several Days = 1
More than half the days = 2
Nearly every day = 3
This means that the GAD-7 is scored out of a maximum of 21, with scores of 8 and above being recognised as the optimal cut-off to optimise sensitivity without compromising specificity for clinically relevant levels of anxiety. With this cut-off, there’s a sensitivity of 92% and a specificity of 76%. Alternatively, a cut-off of 10 or greater has found a sensitivity of 89% with a specificity of 82% for generalised anxiety disorder. This cut-off can also be moderately useful when screening for other anxiety disorders.
For example, a cut-off of 10 has the following sensitivity-specificities:
Panic Disorder: Sensitivity = 74%, specificity = 81%
Social Anxiety Disorder: Sensitivity = 72%, specificity = 80%
PTSD: Sensitivity = 66%, specificity = 81%
It’s important to note that further diagnostic assessment and clinical judgement is required to determine the presence of an anxiety disorder, along with the type of anxiety disorder. However, if you are wanting to track change over time, a meaningful change is 5 or more points on the GAD-7. If an individual has shown scores of less than 5 twice in a row, at least 2 weeks apart, then maintenance treatment may then be most appropriate.
The qualitative labels and their cut-offs provided for the GAD-7, though, are:
Minimal Anxiety = 0-4
Mild Anxiety = 5-9
Moderate Anxiety = 10-14
Severe Anxiety = 15+
Who developed the measures, licensing and how to obtain the GAD-7
The GAD-7 was developed by Dr Robert Spitzer, Dr Janet Willians, Dr Kurt Kroenke and Dr Bernd Löwe. The measure is freely available in the public domain, and no permission is required to reproduce, translate, display or distribute the measure.
The GAD-7 is available on Bravely Connect as part of our automated measures.
Limitations, biases and when you should/shouldn’t use the GAD-7
It is important to highlight that the GAD-7 was validated based on data gathered from 15 primary care clinics in the United States, meaning it’s a Western-centric measure. Although the GAD-7 has been used across a multitude of cultural groups, evidence suggests that the GAD-7 might not be a great fit for many cultures. The prevalence of GAD varies across ethnic/cultural groups, and researchers have argued that this could be due to cross-cultural measurement error rather than actual differences in the rates of GAD across cultures i.e. the GAD-7 has lower sensitivity in some cultures. This theory is supported by a study that found Black/African American people with high generalised anxiety disorder symptoms scores lower on the GAD-7 than participants with comparable symptoms. This suggests that until more culturally sensitive GAD screening tools are developed, the GAD-7 should be used with caution when applied outside of a Western context.
The GAD-7 is a measure that can be consistently used to establish the presence of anxiety disorders symptoms experienced in the last 2 weeks. Therefore, the GAD-7 should not be used to determine historical symptoms, as it’s a snapshot in time, and should instead be used consistently to determine clinically significant change. This means the GAD-7 is useful as a way of determining whether treatment is having a positive impact, and treatment planning.
The GAD-7 is also considered highly effective in identifying moderate to severe anxiety disorders, but is less reliable in identifying individuals with mild symptoms. Therefore, scores below close to the threshold for anxiety symptoms should still be considered in the context of clinical professional evaluations.
As always, if you’ve found a measure you would like adding to Bravely Connect as an automated measure, just drop us a measure request here.
TL;DR: Summary
✅ Available on Bravely Connect
The GAD-7 is a self-report measure used to assess symptoms of generalised anxiety disorder. It consists of 7 questions that ask the client to report how often over the last two weeks they have been bothered by certain symptoms. The measure is scored out of a maximum of 21, with scores of 8 and above being recognized as the optimal cut-off for clinically relevant levels of anxiety. Research suggests that the GAD-7 is able to screen for generalised anxiety disorder and other anxiety disorders to a relatively good level of accuracy, however it’s not considered accurate for low-level anxiety. It has good reliability and criterion, construct, factorial, and procedural validity. The GAD-7 was developed based on the Patient Health Questionnaire (PHQ-9) and there are over 50 translations of the measure available.
Highlights
📏 Lengths: 7 questions (2-5 minutes)
📋 Administration: Self-Report
🎯 Uses: For monitoring symptoms of generalized anxiety, but can also be used for panic, social anxiety, and PTSD.
⚠️ Important Caveats: Not accurate for low-level anxiety
✅ Available in Bravely Connect? Yes
🌏 Culturally Applicable? No (Western-Centric)
💬 Translations? 50+
The GAD-7 Question type and length
The client is presented with 7 questions, and for each question the client is asked to report how often over the last two weeks they have been bothered by the problem.
All questions are statements with the same 4 subjective answers:
Not at all
Several Days
More than half the days
Nearly every day
For the full list of questions check out the measures on Bravely Connect, or follow the following link to the original unautomated version: GAD-7
What does the GAD-7 measure
The GAD-7 measures severity of anxiety symptoms. Research suggests that it’s able to screen for generalised anxiety disorder, but also a variety of other anxiety disorders to a relatively good level of accuracy.
GAD-7 Factor structure
In academic research, factor analyses have been conducted to identify what the underlying constructs are that the GAD-7 is measuring. Across two studies, traditional factor analyses have found a one-factor structure with all questions mapping onto anxiety. However, one of these studies found, via an exploratory graph analysis, a two-factor structure of cognitive-emotional and somatic anxiety. The most relevant symptoms within these factor structures were ‘worrying too much’ and ‘difficulty relaxing’.
The history and theory behind GAD-7
The GAD-7 was developed by Spritzer et al. as a brief measure for assessing generalised anxiety disorder. It was modelled based on the Patient Health Questionnaire (PHQ-9), which measures depression, and was developed because there was no brief clinical measure for assessing generalised anxiety disorder at the time.
They validated their measure in 15 primary care clinics in the United States based on a sample of 2740 adult patients. Criterion and construct validity were established by comparing the diagnoses made via their GAD self-report scale (GAD-7) with those made by independent mental health professionals, functional status measures, disability days, and health care use.
They found the measure to have good reliability, and criterion, construct, factorial, and procedural validity. In factor analyses, they found that generalised anxiety disorder and depression symptoms often co-occurred, but they were found to be distinct dimensions. They also found that the self-report nature of the questionnaire was in strong agreement with interview-administered versions of the scale.
Research has since suggested that the first 4 questions in the GAD-7 align well with anxious disorders, but this is less the case for the final 3 questions. On the back of this, an even shorter version of the GAD-7 was developed called the GAD-2, consisting of just 2 questions.
There are currently over 50 translations of the GAD-7 (find them here)
GAD-7 Scoring Interpretation
The following scores are given for each answer on the GAD-7:
Not at all = 0
Several Days = 1
More than half the days = 2
Nearly every day = 3
This means that the GAD-7 is scored out of a maximum of 21, with scores of 8 and above being recognised as the optimal cut-off to optimise sensitivity without compromising specificity for clinically relevant levels of anxiety. With this cut-off, there’s a sensitivity of 92% and a specificity of 76%. Alternatively, a cut-off of 10 or greater has found a sensitivity of 89% with a specificity of 82% for generalised anxiety disorder. This cut-off can also be moderately useful when screening for other anxiety disorders.
For example, a cut-off of 10 has the following sensitivity-specificities:
Panic Disorder: Sensitivity = 74%, specificity = 81%
Social Anxiety Disorder: Sensitivity = 72%, specificity = 80%
PTSD: Sensitivity = 66%, specificity = 81%
It’s important to note that further diagnostic assessment and clinical judgement is required to determine the presence of an anxiety disorder, along with the type of anxiety disorder. However, if you are wanting to track change over time, a meaningful change is 5 or more points on the GAD-7. If an individual has shown scores of less than 5 twice in a row, at least 2 weeks apart, then maintenance treatment may then be most appropriate.
The qualitative labels and their cut-offs provided for the GAD-7, though, are:
Minimal Anxiety = 0-4
Mild Anxiety = 5-9
Moderate Anxiety = 10-14
Severe Anxiety = 15+
Who developed the measures, licensing and how to obtain the GAD-7
The GAD-7 was developed by Dr Robert Spitzer, Dr Janet Willians, Dr Kurt Kroenke and Dr Bernd Löwe. The measure is freely available in the public domain, and no permission is required to reproduce, translate, display or distribute the measure.
The GAD-7 is available on Bravely Connect as part of our automated measures.
Limitations, biases and when you should/shouldn’t use the GAD-7
It is important to highlight that the GAD-7 was validated based on data gathered from 15 primary care clinics in the United States, meaning it’s a Western-centric measure. Although the GAD-7 has been used across a multitude of cultural groups, evidence suggests that the GAD-7 might not be a great fit for many cultures. The prevalence of GAD varies across ethnic/cultural groups, and researchers have argued that this could be due to cross-cultural measurement error rather than actual differences in the rates of GAD across cultures i.e. the GAD-7 has lower sensitivity in some cultures. This theory is supported by a study that found Black/African American people with high generalised anxiety disorder symptoms scores lower on the GAD-7 than participants with comparable symptoms. This suggests that until more culturally sensitive GAD screening tools are developed, the GAD-7 should be used with caution when applied outside of a Western context.
The GAD-7 is a measure that can be consistently used to establish the presence of anxiety disorders symptoms experienced in the last 2 weeks. Therefore, the GAD-7 should not be used to determine historical symptoms, as it’s a snapshot in time, and should instead be used consistently to determine clinically significant change. This means the GAD-7 is useful as a way of determining whether treatment is having a positive impact, and treatment planning.
The GAD-7 is also considered highly effective in identifying moderate to severe anxiety disorders, but is less reliable in identifying individuals with mild symptoms. Therefore, scores below close to the threshold for anxiety symptoms should still be considered in the context of clinical professional evaluations.
As always, if you’ve found a measure you would like adding to Bravely Connect as an automated measure, just drop us a measure request here.
Transform your therapy practice with Bravely Connect
Embrace the future of therapy with Bravely Connect. Say goodbye to the hassle of admin, and hello to better client engagement and therapeutic alliance.
With seamless management of scheduling, records, and outcomes, you're ready to elevate your practice. Discover the Bravely Connect difference and start a new era of streamlined practice management!
Transform your therapy practice with Bravely Connect
Embrace the future of therapy with Bravely Connect. Say goodbye to the hassle of admin, and hello to better client engagement and therapeutic alliance.
With seamless management of scheduling, records, and outcomes, you're ready to elevate your practice. Discover the Bravely Connect difference and start a new era of streamlined practice management!
Transform your therapy practice with Bravely Connect
Embrace the future of therapy with Bravely Connect. Say goodbye to the hassle of admin, and hello to better client engagement and therapeutic alliance.
With seamless management of scheduling, records, and outcomes, you're ready to elevate your practice. Discover the Bravely Connect difference and start a new era of streamlined practice management!
author
Bravely
Tech for therapists
Behind Bravely is a team of passionate and determined researchers, psychologists, designers and developers — who are, above all, human beings who know what it’s like to struggle with their mental health.
bravely.io · linkedin · instagram
Insights flown
directly to your inbox
Stay in the loop with articles from fellow practitioners, how-to guides and news from Bravely
Insights flown
directly to your inbox
Stay in the loop with articles from fellow practitioners, how-to guides and news from Bravely
Insights flown
directly to your inbox
Stay in the loop with articles from fellow practitioners, how-to guides and news from Bravely
Keep reading
Keep reading
Keep reading
General
General
Gender disparities in outcome measures
Gender disparities in outcome measures
27 Apr 2024
General
General
Why Measurement Based Care?
Why Measurement Based Care?
5 Apr 2024
Measures Guide
Measures Guide
Perinatal Anxiety Screening Scale (PASS)
Perinatal Anxiety Screening Scale (PASS)
12 Mar 2024
Measures Guide
Measures Guide
Mastering the OLBI: Understanding the Oldenburg Burnout Inventory
Mastering the OLBI: Understanding the Oldenburg Burnout Inventory
25 Nov 2023
Measures Guide
Measures Guide
Alcohol Use Disorders Identification Test (AUDIT-C)
Alcohol Use Disorders Identification Test (AUDIT-C)
21 Nov 2023
Bravely Connect
Bravely Connect
Bravely Connect launches today!
Bravely Connect launches today!
20 Sept 2023
Bravely Connect
Bravely Connect
Supercharging therapeutic alliances; How tech can boost the most valuable tool for therapy
Supercharging therapeutic alliances; How tech can boost the most valuable tool for therapy
10 Aug 2023
Measures Guide
Measures Guide
Work and Social Adjustment Scale (WSAS)
Work and Social Adjustment Scale (WSAS)
14 Jun 2023
Measures Guide
Measures Guide
The Oldenburg Burnout Inventory (OLBI)
The Oldenburg Burnout Inventory (OLBI)
13 May 2023
Community
Community
Dr. Carol Lee on tech, inclusivity, and the importance of accessible research
Dr. Carol Lee on tech, inclusivity, and the importance of accessible research
8 May 2023
Measures Guide
Measures Guide
Perceived Stress Scale (PSS)
Perceived Stress Scale (PSS)
1 Mar 2023
Measures Guide
Measures Guide
Patient Health Questionnaire(s) (PHQ-2, PHQ-4, PHQ-8)
Patient Health Questionnaire(s) (PHQ-2, PHQ-4, PHQ-8)
24 Feb 2023
Measures Guide
Measures Guide
Autism Spectrum Quotient (AQ)
Autism Spectrum Quotient (AQ)
18 Feb 2023
Measures Guide
Measures Guide
PTSD Checklist for DSM-5 (PCL-5)
PTSD Checklist for DSM-5 (PCL-5)
12 Feb 2023
Measures Guide
Measures Guide
Kessler Psychological Distress Scale (K10)
Kessler Psychological Distress Scale (K10)
4 Feb 2023
Measures Guide
Measures Guide
Short Form Health Survey (SF-36)
Short Form Health Survey (SF-36)
30 Jan 2023
Measures Guide
Measures Guide
Generalised Anxiety Disorder Assessment (GAD-7)
Generalised Anxiety Disorder Assessment (GAD-7)
14 Jan 2023
Measures Guide
Measures Guide
The Positive and Negative Affect Schedule (PANAS)
The Positive and Negative Affect Schedule (PANAS)
4 Dec 2022
Measures Guide
Measures Guide
Penn State Worry Questionnaire (PSWQ)
Penn State Worry Questionnaire (PSWQ)
14 Nov 2022
General
General
The HALT: A quick, self check-in
The HALT: A quick, self check-in
17 Dec 2021
Measures Guide
Measures Guide
Depression Anxiety and Stress Scale (DASS)
Depression Anxiety and Stress Scale (DASS)
4 Dec 2021
Stories
Stories
The trauma that surrounds us
The trauma that surrounds us
11 Aug 2021
Bravely Home Mobile App
Bravely Home Mobile App
What happens to my data on Bravely's mobile app? Our data privacy ethos
What happens to my data on Bravely's mobile app? Our data privacy ethos
8 Aug 2021
General
General
Remotely social: Improving workplace wellbeing
Remotely social: Improving workplace wellbeing
15 Jul 2021
General
General
Give your employees the mental health support they need
Give your employees the mental health support they need
21 Jun 2021
Stories
Stories
Mental illness is invisible and doesn’t discriminate. But some people do.
Mental illness is invisible and doesn’t discriminate. But some people do.
12 Feb 2020
Stories
Stories
Why Bravely — how my mental health struggles led me to start a new venture.
Why Bravely — how my mental health struggles led me to start a new venture.
20 Aug 2019
Streamlining your mental health practice with simplified scheduling, tracking, assignments, outcome scoring and client documentation. By elevating client engagement and motivation, you can create a collaborative experience you both will love.
FOR INDIVIDUALS
Made with ❤️ from
© 2023 Bravely Tech Pte Ltd.
Streamlining your mental health practice with simplified scheduling, tracking, assignments, outcome scoring and client documentation. By elevating client engagement and motivation, you can create a collaborative experience you both will love.
FOR INDIVIDUALS
Made with ❤️ from
© 2023 Bravely Tech Pte Ltd.
Streamlining your mental health practice with simplified scheduling, tracking, assignments, outcome scoring and client documentation. By elevating client engagement and motivation, you can create a collaborative experience you both will love.
FOR INDIVIDUALS
Made with ❤️ from
© 2023 Bravely Tech Pte Ltd.